ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
九源基因
7.950
-0.360
-4.33%
手動刷新
成交量:
3.66萬
成交額:
29.01萬
市值:
19.24億
市盈率:
11.71
高:
8.180
開:
8.040
低:
7.840
收:
8.310
52周最高:
16.290
52周最低:
5.330
股本:
2.42億
香港流通股本:
1.06億
量比:
1.25
換手率:
0.03%
股息:
0.06
股息率:
0.80%
每股收益(LYR):
0.679
淨資產收益率:
9.48%
總資產收益率:
4.45%
市淨率:
1.06
市盈率(LYR):
11.71
市銷率:
1.30
資料載入中...
總覽
公司
新聞資訊
公告
九源基因(02566)公布1月股份變動月報,合計回購約77.44萬股H股
公告速递
·
03/18
九源基因(02566):JY47注射液新藥臨床試驗申請獲國家藥監局臨床試驗默示許可
智通财经
·
03/17
九源基因Jy47注射液臨床試驗申請獲國家藥監局批准
美股速递
·
03/17
九源基因(02566.HK)公眾持股量約為22.22%
中金财经
·
03/05
九源基因(02566)公告:公眾持股量降至22.22% 正研究恢復至25%最低比例
公告速递
·
03/05
九源基因(02566)2月回購3,108,000股H股,註冊股本維持245,398,800股
公告速递
·
03/04
九源基因(02566)股價下跌5.333%,現價港幣$8.52
阿斯达克财经
·
03/02
國產減重藥迎突破!九源基因司美格魯肽申報上市 瞄準百億美元賽道
大湾区经济网
·
02/26
九源基因(02566):吉可親®上市申請獲國家藥品監督管理局受理
智通财经
·
02/25
九源基因(02566)股價下跌6.466%,現價港幣$8.68
阿斯达克财经
·
02/24
九源基因2026年關注點:司美格魯肽專利到期與新品臨床試驗
新浪财经
·
02/23
九源基因盤中異動 股價大漲8.49%
市场透视
·
02/23
九源基因(02566)股價下跌5.01%,現價港幣$9.1
阿斯达克财经
·
02/20
九源基因(02566)2月12日耗資約25.53萬港元回購2.6萬股
智通财经
·
02/12
九源基因(02566)2月11日斥資8.51萬港元回購8600股
智通财经
·
02/11
杭州九源基因生物醫藥(02566)回購8,600股H股,佔已發行股本約0.00817%
公告速递
·
02/11
杭州九源基因(02566)回購約28.52萬股H股,總額約287萬港元
公告速递
·
02/10
九源基因(02566)2月9日斥資60.59萬港元回購6.08萬股
智通财经
·
02/09
杭州九源基因(02566)回購6.08萬股股份,總額約60.59萬港元
公告速递
·
02/09
助血糖控制及體重管理 九源基因(02566.HK)JY54注射液臨床試驗申請獲受理
阿斯达克财经
·
02/09
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02566/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02566","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02566\",,,,,undefined,":{"symbol":"02566","market":"HK","secType":"STK","nameCN":"九源基因","latestPrice":7.95,"timestamp":1774247535780,"preClose":8.31,"halted":0,"volume":36600,"delay":0,"changeRate":-0.0433212996389892,"floatShares":106000000,"shares":242000000,"eps":0.678655,"marketStatus":"交易中","change":-0.36,"latestTime":"03-23 14:35:34","open":8.04,"high":8.18,"low":7.84,"amount":290136,"amplitude":0.040915,"askPrice":7.96,"askSize":2800,"bidPrice":7.95,"bidSize":4200,"shortable":0,"etf":0,"ttmEps":0.559,"tradingStatus":2,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1774253400000},"marketStatusCode":2,"adr":0,"listingDate":1732723200000,"exchange":"SEHK","adjPreClose":8.31,"dividendRate":0.007933,"openAndCloseTimeList":[[1774229400000,1774238400000],[1774242000000,1774252800000]],"volumeRatio":1.249938,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02566\",,,,,undefined,":{"symbol":"02566","floatShares":106000000,"roa":"4.45%","roe":"9.48%","lyrEps":0.678655,"volumeRatio":1.249938,"shares":242000000,"dividePrice":0.063403,"high":8.18,"amplitude":0.040915,"preClose":8.31,"low":7.84,"week52Low":5.33,"pbRate":"1.06","psRate":"1.30","week52High":16.29,"institutionHeld":0,"latestPrice":7.95,"committee":0.2,"eps":0.678655,"divideRate":0.007975,"volume":36600,"delay":0,"ttmEps":0.559,"open":8.04,"prevYearClose":7.56,"prevWeekClose":8.31,"prevMonthClose":9,"prevQuarterClose":7.56,"fiveDayClose":7.69,"twentyDayClose":9.28,"sixtyDayClose":7.73,"earningDate":1774800000000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02566\",params:#limit:5,,,undefined,":[{"date":"2026-03-30","symbol":"02566","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null},{"date":"2025-08-18","symbol":"02566","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755480600000,"name":null,"time":"","dateTimestamp":1755446400000,"actualEps":null},{"date":"2025-06-13","symbol":"02566","amount":0.056,"announcedDate":"2025-03-26","type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2025-06-16","defaultRemindTime":1749778200000,"name":"九源基因","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-30","payableDate":"2025-06-16","currency":"CNY","dateTimestamp":1749744000000,"payDate":"2025-07-30"},{"date":"2025-03-26","symbol":"02566","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742952600000,"name":null,"time":"","dateTimestamp":1742918400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02566\",market:\"HK\",,,undefined,":[{"executeDate":"2025-06-13","recordDate":"2025-06-16","paymentDate":"2025-07-30","value":0.056,"currency":"CNY"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02566\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02566\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02566","date":"2026-03-20","current":14.168157,"percent":0.578616,"low":9.307514,"twenty":11.037013,"median":13.985049,"eighty":17.25142,"high":28.852596,"avg":14.79383,"sd":4.217488,"marketCap":2007001284},"quantilePoints":[{"date":"2024-12-06","current":14.097915,"twenty":14.208262,"median":14.275695,"eighty":14.595644,"marketCap":1946012484},{"date":"2024-12-13","current":13.217326,"twenty":13.348436,"median":13.95821,"eighty":14.334483,"marketCap":1820859096},{"date":"2024-12-20","current":12.20261,"twenty":12.40882,"median":13.381214,"eighty":14.243818,"marketCap":1673619816},{"date":"2024-12-27","current":12.158366,"twenty":12.254449,"median":13.1954,"eighty":14.180675,"marketCap":1666257852},{"date":"2025-01-03","current":11.126814,"twenty":12.0799,"median":12.46117,"eighty":14.042033,"marketCap":1526380536},{"date":"2025-01-10","current":9.714633,"twenty":11.141125,"median":12.29741,"eighty":13.763077,"marketCap":1327607508},{"date":"2025-01-17","current":9.904165,"twenty":10.518129,"median":12.180488,"eighty":13.509332,"marketCap":1354601376},{"date":"2025-01-24","current":10.07429,"twenty":9.9409,"median":12.04207,"eighty":13.348436,"marketCap":1386503220},{"date":"2025-01-28","current":10.358786,"twenty":9.995541,"median":11.819979,"eighty":13.282881,"marketCap":1433128992},{"date":"2025-02-07","current":11.238302,"twenty":10.0243,"median":11.162591,"eighty":13.191014,"marketCap":1546012440},{"date":"2025-02-14","current":11.154484,"twenty":10.062805,"median":11.126814,"eighty":12.776093,"marketCap":1533742500},{"date":"2025-02-21","current":12.73316,"twenty":10.073062,"median":11.193598,"eighty":12.735779,"marketCap":1757055408},{"date":"2025-02-28","current":11.508443,"twenty":10.189099,"median":11.508443,"eighty":12.653552,"marketCap":1582822260},{"date":"2025-03-07","current":12.084413,"twenty":10.276651,"median":11.554796,"eighty":12.584056,"marketCap":1668711840},{"date":"2025-03-14","current":12.91496,"twenty":10.28916,"median":11.611229,"eighty":12.584056,"marketCap":1784049276},{"date":"2025-03-21","current":12.244709,"twenty":10.311241,"median":11.810026,"eighty":12.735779,"marketCap":1690797732},{"date":"2025-03-28","current":11.696332,"twenty":10.344738,"median":11.831112,"eighty":12.72799,"marketCap":1734969516},{"date":"2025-04-03","current":10.807781,"twenty":10.395616,"median":11.800074,"eighty":12.674918,"marketCap":1600000176},{"date":"2025-04-11","current":9.828764,"twenty":10.27298,"median":11.65378,"eighty":12.589531,"marketCap":1445398932},{"date":"2025-04-17","current":9.988361,"twenty":10.075173,"median":11.569961,"eighty":12.56072,"marketCap":1472392800},{"date":"2025-04-25","current":10.079541,"twenty":10.050182,"median":11.463659,"eighty":12.511173,"marketCap":1487116728},{"date":"2025-05-02","current":10.290636,"twenty":10.067013,"median":11.287756,"eighty":12.494061,"marketCap":1467484824},{"date":"2025-05-09","current":10.406872,"twenty":10.062805,"median":11.203375,"eighty":12.472285,"marketCap":1494478692},{"date":"2025-05-16","current":10.339488,"twenty":10.073062,"median":11.154484,"eighty":12.457737,"marketCap":1496932680},{"date":"2025-05-23","current":10.443848,"twenty":10.076938,"median":11.100884,"eighty":12.429027,"marketCap":1516564584},{"date":"2025-05-30","current":10.499086,"twenty":10.079206,"median":11.063697,"eighty":12.408842,"marketCap":1531288512},{"date":"2025-06-06","current":10.405237,"twenty":10.102813,"median":10.92653,"eighty":12.402573,"marketCap":1521472560},{"date":"2025-06-13","current":16.776007,"twenty":10.127345,"median":11.063697,"eighty":12.429027,"marketCap":2453988000},{"date":"2025-06-20","current":13.783342,"twenty":10.148232,"median":11.100884,"eighty":12.535947,"marketCap":2012270160},{"date":"2025-06-27","current":13.241991,"twenty":10.175286,"median":11.154484,"eighty":12.72799,"marketCap":1938650520},{"date":"2025-07-04","current":14.247042,"twenty":10.191457,"median":11.198369,"eighty":12.80722,"marketCap":2085889800},{"date":"2025-07-11","current":16.12378,"twenty":10.199228,"median":11.287756,"eighty":13.164345,"marketCap":2358282468},{"date":"2025-07-18","current":16.959198,"twenty":10.204599,"median":11.508443,"eighty":13.325525,"marketCap":2478527880},{"date":"2025-07-25","current":16.429296,"twenty":10.22327,"median":11.606189,"eighty":13.872228,"marketCap":2409816216},{"date":"2025-08-01","current":16.329429,"twenty":10.25109,"median":11.703755,"eighty":14.068336,"marketCap":2380368360},{"date":"2025-08-08","current":17.296232,"twenty":10.27298,"median":11.825546,"eighty":14.242565,"marketCap":2527607640},{"date":"2025-08-15","current":25.546022,"twenty":10.28665,"median":12.04207,"eighty":14.454008,"marketCap":3727607772},{"date":"2025-08-22","current":27.152477,"twenty":10.291424,"median":12.068084,"eighty":15.48419,"marketCap":3646626168},{"date":"2025-08-29","current":24.186548,"twenty":10.297713,"median":12.158366,"eighty":16.326447,"marketCap":3263804040},{"date":"2025-09-05","current":26.17651,"twenty":10.31224,"median":12.214209,"eighty":16.547432,"marketCap":3528834744},{"date":"2025-09-12","current":23.22216,"twenty":10.322989,"median":12.270192,"eighty":16.690567,"marketCap":3136196664},{"date":"2025-09-19","current":21.82033,"twenty":10.32445,"median":12.326094,"eighty":16.958366,"marketCap":2944785600},{"date":"2025-09-26","current":20.564467,"twenty":10.331172,"median":12.407292,"eighty":17.223519,"marketCap":2768098464},{"date":"2025-10-03","current":22.006879,"twenty":10.341379,"median":12.455816,"eighty":17.606421,"marketCap":2969325480},{"date":"2025-10-10","current":19.015463,"twenty":10.348945,"median":12.489783,"eighty":18.310381,"marketCap":2561963472},{"date":"2025-10-17","current":16.970486,"twenty":10.358786,"median":12.586793,"eighty":18.134776,"marketCap":2284662828},{"date":"2025-10-24","current":16.253675,"twenty":10.405237,"median":12.724544,"eighty":17.900127,"marketCap":2188957296},{"date":"2025-10-31","current":15.392522,"twenty":10.406545,"median":12.739707,"eighty":17.871014,"marketCap":2076073848},{"date":"2025-11-07","current":13.654382,"twenty":10.406872,"median":12.862233,"eighty":17.830642,"marketCap":1840491000},{"date":"2025-11-14","current":13.652109,"twenty":10.414705,"median":13.150654,"eighty":17.669327,"marketCap":1845398976},{"date":"2025-11-21","current":13.022772,"twenty":10.429703,"median":12.977364,"eighty":17.532486,"marketCap":1759509396},{"date":"2025-11-28","current":14.151953,"twenty":10.441671,"median":13.150654,"eighty":17.476552,"marketCap":1919018616},{"date":"2025-12-05","current":15.0671,"twenty":10.446315,"median":13.212896,"eighty":17.360095,"marketCap":2046625992},{"date":"2025-12-12","current":15.021249,"twenty":10.450076,"median":13.373682,"eighty":17.303573,"marketCap":2044172004},{"date":"2025-12-19","current":13.906512,"twenty":10.4562,"median":13.596735,"eighty":17.18567,"marketCap":1896932724},{"date":"2025-12-24","current":13.468772,"twenty":10.460694,"median":13.541362,"eighty":17.140598,"marketCap":1842944988},{"date":"2026-01-02","current":13.594612,"twenty":10.472165,"median":13.526709,"eighty":17.103787,"marketCap":1867484868},{"date":"2026-01-09","current":14.184539,"twenty":10.508332,"median":13.623361,"eighty":17.043007,"marketCap":1953374448},{"date":"2026-01-16","current":15.82386,"twenty":10.552044,"median":13.654647,"eighty":16.970089,"marketCap":2186209278},{"date":"2026-01-23","current":17.221546,"twenty":10.59039,"median":13.760784,"eighty":17.043007,"marketCap":2377029620},{"date":"2026-01-30","current":18.645413,"twenty":10.66635,"median":13.818506,"eighty":17.208843,"marketCap":2585326030},{"date":"2026-02-06","current":17.570145,"twenty":10.791312,"median":13.890789,"eighty":17.500019,"marketCap":2442411318},{"date":"2026-02-13","current":16.566637,"twenty":10.808038,"median":13.930604,"eighty":17.447639,"marketCap":2316142276},{"date":"2026-02-20","current":15.898541,"twenty":10.808553,"median":13.936612,"eighty":17.405456,"marketCap":2219535716},{"date":"2026-02-27","current":15.400942,"twenty":10.876548,"median":13.991046,"eighty":17.345071,"marketCap":2173647600},{"date":"2026-03-06","current":14.146009,"twenty":10.927529,"median":14.014987,"eighty":17.323365,"marketCap":1980434480},{"date":"2026-03-13","current":13.445786,"twenty":10.970802,"median":13.989227,"eighty":17.304533,"marketCap":1891073412},{"date":"2026-03-20","current":14.324288,"twenty":11.037013,"median":13.985049,"eighty":17.25142,"marketCap":2007001284}],"updateTime":1774231722463},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02566\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1125248160","title":"九源基因(02566)公布1月股份變動月報,合計回購約77.44萬股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1125248160","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125248160?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 18:21","pubTimestamp":1773829312,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司于2026年3月18日披露2026年1月股份变动月报表,报告期为2026年1月。截至本月末,公司注册股本人民币245,398,800元,其中包括三类股份:H股、内资股及非上市外资股。H股方面,月初已发行流通股份数量为109,096,785股,当月合计回购774,400股,并将其持作库存股份,导致H股流通股份减少至108,322,385股,库存股份则增至774,400股。内资股和非上市外资股数量分别维持在105,302,015股及31,000,000股,报告期内无变动。截至1月末,公司股本总数保持稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"gpt_icon":0},{"id":"2620430440","title":"九源基因(02566):JY47注射液新藥臨床試驗申請獲國家藥監局臨床試驗默示許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2620430440","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620430440?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 17:21","pubTimestamp":1773739274,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九源基因(02566)发布公告,集团自主开发的JY47注射液新药临床试验(IND)申请已获中国国家药品监督管理局临床试验默示许可,适应症为代谢功能障碍相关脂肪性肝炎(MASH)伴肝纤维化。该产品为集团研发的一款靶向SIRPα的单抗注射液。SIRPα是典型的抑制性受体,可与配体CD47以高亲和力结合。研究表明CD47-SIRPα信号通路在代谢性疾病相关的免疫调控中具有重要作用,SIRP拮抗剂可通过调节免疫细胞功能、改善组织微环境及代谢稳态,从而对代谢疾病进展产生积极影响。在MASH的体外类器官模型和体内疾病模型中,显示出良好的治疗潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"1110359935","title":"九源基因Jy47注射液臨床試驗申請獲國家藥監局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1110359935","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110359935?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 17:20","pubTimestamp":1773739217,"startTime":"0","endTime":"0","summary":"杭州九源基因工程股份有限公司宣布,其Jy47注射液的临床试验申请已获得国家药品监督管理局的正式批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566","BK1161"],"gpt_icon":0},{"id":"2617854431","title":"九源基因(02566.HK)公眾持股量約為22.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617854431","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617854431?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 20:07","pubTimestamp":1772712421,"startTime":"0","endTime":"0","summary":"格隆汇3月5日丨九源基因(02566.HK)公告,于本公告日期,公司的公众持股量约为22.22%,已低于上市规则第19A.28B条所规定公众股东持有公司已发行股份总数的25.0%(\"最低规定百分比\")。\r\n\r\n 公司公众持股量的不足,乃由于近期根据公司股东于2025年6月11日举行的股东周年大会上授予董事会的购回授权,回购公司H股所致,使得其中一名公众股东转变成为上市规则所定义的主要股东。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260305/32047782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02566","BK1161"],"gpt_icon":0},{"id":"1152661765","title":"九源基因(02566)公告:公眾持股量降至22.22% 正研究恢復至25%最低比例","url":"https://stock-news.laohu8.com/highlight/detail?id=1152661765","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152661765?lang=zh_tw&edition=fundamental","pubTime":"2026-03-05 19:51","pubTimestamp":1772711502,"startTime":"0","endTime":"0","summary":"九源基因于2026年3月5日发布公告,指出上市公司公众持股量约为22.22%,低于香港联合交易所有限公司证券上市规则所要求的最低25%规定。据悉,主要原因在于根据2025年6月11日股东周年大会上授予董事会的购回授权回购H股后,一名原本属于公众持股范围的股东转变为上市规则定义的主要股东,导致公众持股量减少。公司预计自公告日期起六个月内恢复公众持股量,但仍需董事会和监管机构批准,并视乎市场情况而定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"gpt_icon":0},{"id":"1144352339","title":"九源基因(02566)2月回購3,108,000股H股,註冊股本維持245,398,800股","url":"https://stock-news.laohu8.com/highlight/detail?id=1144352339","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144352339?lang=zh_tw&edition=fundamental","pubTime":"2026-03-04 17:41","pubTimestamp":1772617313,"startTime":"0","endTime":"0","summary":"九源基因于2026年3月4日披露了截至2026年2月28日的股份变动月报表。公告显示,公司本月注册股本保持人民币245,398,800元不变,未有新增发行或注销事项。本月内,公司H股总数维持109,096,785股,其中流通中的已发行股份由上月底的108,322,385股减少至105,214,385股,变化主要因回购3,108,000股H股所致。这些回购股份尚未注销,暂以库存股份形式持有,数量由774,400股增至3,882,400股。内资股与非上市外资股方面,数量分别保持105,302,015股与31,000,000股,均无变动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"gpt_icon":0},{"id":"2616389893","title":"九源基因(02566)股價下跌5.333%,現價港幣$8.52","url":"https://stock-news.laohu8.com/highlight/detail?id=2616389893","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616389893?lang=zh_tw&edition=fundamental","pubTime":"2026-03-02 15:45","pubTimestamp":1772437500,"startTime":"0","endTime":"0","summary":"[下跌股]九源基因(02566) 股价在下午03:45比前收市价下跌5.333%,现股价为港币$8.52。至目前为止,今日最高价为$9.0,而最低价为$8.52。总成交量为11.24万股,总成交金额为港币$98.15万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603028423/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603028423/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2614029090","title":"國產減重藥迎突破!九源基因司美格魯肽申報上市 瞄準百億美元賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2614029090","media":"大湾区经济网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614029090?lang=zh_tw&edition=fundamental","pubTime":"2026-02-26 10:12","pubTimestamp":1772071957,"startTime":"0","endTime":"0","summary":"在国内司美格鲁肽减重适应症领域,公司属于少数已完成上市申报并进入审评阶段的企业之一。相关产品如顺利获批,有望成为国内首个以生物法实现产业化的司美格鲁肽减重药物。公开数据显示,司美格鲁肽减重产品在中国市场实现快速增长,2025年诺和诺德司美格鲁肽减重版注射液中国区销售额为1.21亿美元,同比激增314%,市场对高品质减重药物的需求日益迫切。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226101341a4c95f06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226101341a4c95f06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2614608029","title":"九源基因(02566):吉可親®上市申請獲國家藥品監督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2614608029","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614608029?lang=zh_tw&edition=fundamental","pubTime":"2026-02-25 21:44","pubTimestamp":1772027076,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九源基因 发布公告,集团开发的吉可亲的上市申请已获中国国家药监局受理。吉可亲于2024年1月获得国家药品监督管理局签发的药物临床试验批准通知书,并于2024年12月完成Ⅲ期临床研究全部受试者入组,目前已完成试验,上市申请相关申报资料已递交国家药品审评中心进行审评。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"九源基因(02566):吉可亲®上市申请获国家药品监督管理局受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2613697761","title":"九源基因(02566)股價下跌6.466%,現價港幣$8.68","url":"https://stock-news.laohu8.com/highlight/detail?id=2613697761","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613697761?lang=zh_tw&edition=fundamental","pubTime":"2026-02-24 13:30","pubTimestamp":1771911000,"startTime":"0","endTime":"0","summary":"[下跌股]九源基因(02566) 股价在下午01:30比前收市价下跌6.466%,现股价为港币$8.68。至目前为止,今日最高价为$9.2,而最低价为$8.68。总成交量为1.52万股,总成交金额为港币$13.738万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131625844_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2602245606/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2602245606/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2613733439","title":"九源基因2026年關注點:司美格魯肽專利到期與新品臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2613733439","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613733439?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 17:43","pubTimestamp":1771839834,"startTime":"0","endTime":"0","summary":"来源:经济观察网经济观察网 根据公开信息,九源基因在2026年有以下值得关注的事件:行业政策与环境司美格鲁肽专利到期及市场竞争变化:司美格鲁肽核心专利将于2026年3月后到期,预计国产司美格鲁肽将进入市场竞争加剧的阶段,九源基因是申报该产品的企业之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223174806a7158f38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223174806a7158f38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02566","BK1161"],"gpt_icon":0},{"id":"2613207749","title":"九源基因盤中異動 股價大漲8.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613207749","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613207749?lang=zh_tw&edition=fundamental","pubTime":"2026-02-23 09:31","pubTimestamp":1771810290,"startTime":"0","endTime":"0","summary":"2026年02月23日早盘09时31分,九源基因股票出现波动,股价急速上涨8.49%。截至发稿,该股报9.970港元/股,成交量1.1万股,换手率0.01%,振幅0.00%。九源基因股票所在的药品行业中,整体涨幅为0.27%。其相关个股中,九源基因、德琪医药-B、长风药业涨幅较大,振幅较大的相关个股有康龙化成、康哲药业、中国同辐,振幅分别为3.48%、2.38%、2.34%。九源基因公司简介:杭州九源基因工程有限公司是一家主要从事基因药物研发的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602230931309541a2c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602230931309541a2c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2612255839","title":"九源基因(02566)股價下跌5.01%,現價港幣$9.1","url":"https://stock-news.laohu8.com/highlight/detail?id=2612255839","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612255839?lang=zh_tw&edition=fundamental","pubTime":"2026-02-20 11:21","pubTimestamp":1771557660,"startTime":"0","endTime":"0","summary":"[下跌股]九源基因(02566) 股价在上午11:21比前收市价下跌5.01%,现股价为港币$9.1。至目前为止,今日最高价为$9.58,而最低价为$9.1。总成交量为2.72万股,总成交金额为港币$25.379万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152742524_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2602203754/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2602203754/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2610794209","title":"九源基因(02566)2月12日耗資約25.53萬港元回購2.6萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610794209","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610794209?lang=zh_tw&edition=fundamental","pubTime":"2026-02-12 19:03","pubTimestamp":1770894192,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九源基因(02566)公布,2026年2月12日耗资约25.53万港元回购2.6万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404787.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2610936857","title":"九源基因(02566)2月11日斥資8.51萬港元回購8600股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610936857","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610936857?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 18:54","pubTimestamp":1770807244,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九源基因(02566)发布公告,该公司于2026年2月11日斥资8.51万港元回购8600股股份,每股回购价格为9.89-9.9港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02566","BK1161"],"gpt_icon":0},{"id":"1114194197","title":"杭州九源基因生物醫藥(02566)回購8,600股H股,佔已發行股本約0.00817%","url":"https://stock-news.laohu8.com/highlight/detail?id=1114194197","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114194197?lang=zh_tw&edition=fundamental","pubTime":"2026-02-11 18:45","pubTimestamp":1770806730,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司于2026年2月11日发布翌日披露报表,公告公司于当日回购8,600股H股,约占公司回购前已发行股份总数的0.00817%。本次回购价格介乎每股9.89港元至9.90港元,总金额约85,107.9994港元。公司亦披露,剩余回购授权基于2025年6月11日通过的议案,授权总数为10,909,678股,此前已回购3,856,400股。公司在公告中确认,此次回购遵守香港联交所证券上市规则及相关法律规定,相关董事会授权亦已获得正式批准。公告由联席公司秘书黄秀签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"gpt_icon":0},{"id":"1103066878","title":"杭州九源基因(02566)回購約28.52萬股H股,總額約287萬港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103066878","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103066878?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 19:01","pubTimestamp":1770721311,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司(02566)于2026年2月10日发布翌日披露报表,披露当日回购285,200股H股,占回购前公司已发行股份(不包括库藏股)的约0.27024%。\n本次回购于香港联交所进行,价格区间介于每股9.83港元至10.30港元之间,合计支付约2,870,506.048港元。根据2025年6月11日获通过的购回授权,公司剩余可回购股份数为10,909,678股。回购完成后,公司已发行股份总数维持在109,096,785股,其中流通股为105,248,985股,库藏股为3,847,800股。\n公司确认已严格遵守相关上市规则及法律规定。公告由联席公司秘书黄秀签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"gpt_icon":0},{"id":"2610756637","title":"九源基因(02566)2月9日斥資60.59萬港元回購6.08萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610756637","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610756637?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 20:13","pubTimestamp":1770639185,"startTime":"0","endTime":"0","summary":"智通财经APP讯,九源基因(02566)发布公告,于2026年2月9日,该公司斥资60.59万港元回购6.08万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"1194403275","title":"杭州九源基因(02566)回購6.08萬股股份,總額約60.59萬港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194403275","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194403275?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 19:51","pubTimestamp":1770637908,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司于2026年2月9日公布翌日披露报表,披露当日回购60,800股H股股份,约占回购前已发行股本的0.05758%。本次回购每股价格在每股港币9.81元至10元区间,总额约港币60.59万元。据公告显示,本次回购基于2025年6月11日通过的回购授权进行,公司目前可回购股份总数为10,909,678股,截至公告日已回购3,562,600股。公司确认已遵守香港联合交易所有限公司证券上市规则及相关法律规定。公告由联席公司秘书黄秀签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"gpt_icon":0},{"id":"2610633921","title":"助血糖控制及體重管理 九源基因(02566.HK)JY54注射液臨床試驗申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2610633921","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610633921?lang=zh_tw&edition=fundamental","pubTime":"2026-02-09 17:04","pubTimestamp":1770627840,"startTime":"0","endTime":"0","summary":"九源基因宣布,公司自主开发的化学1类创新药“JY54注射液”新药临床试验申请,已获国家药品监督管理局药品审评中心正式受理。公司计划开展“JY54注射液”用于肥胖或超重人群体重管理的Ⅰ期临床研究,该研究旨在评价“JY54注射液”在受试者中的安全性、耐受性、药代动力学和药效动力学。据介绍,“JY54注射液”是公司自主研发的一款长效胰淀素类似物。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20241126155519150_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20241126155519150_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1502069/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1502069/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02566"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":81,"code":"91000000","status":"200"}]}}